Myeloma survival has shifted fast enough that one global estimate puts deaths in 2018 at about 114,000, yet modern study cohorts now report 5 year relative survival rising from 30% in 1975 to 50% in 2007 to 2011. From SEER 18 covering 34.6% of the US population to trials where maintenance lenalidomide nearly doubles progression free survival, the evidence is full of meaningful, testable contrasts rather than vague optimism. By piecing together these outcomes and the role of MRD, you can see where today’s gains come from and where they still fall short.
Key Takeaways
- The SEER 18 registry database covers 34.6% of the U.S. population
- A population-based study reported that 5-year relative survival for multiple myeloma increased from 30% (1975–1979) to 50% (2007–2011)
- In 2018, multiple myeloma deaths globally were estimated at ~114,000 (2018 estimates)
- The hazard ratio for overall survival associated with maintenance lenalidomide in meta-analyses is typically ~0.7 (i.e., about 30% relative reduction)
- In the IFM 2005-02 trial, maintenance lenalidomide increased median progression-free survival from 20 to 41 months
- In CALGB 100104, maintenance lenalidomide improved median progression-free survival to 46.1 months vs 27.5 months with placebo
- A European population study reported a median overall survival of 5.1 years for multiple myeloma in the modern era cohort
- Cancer drug development spending in the U.S. reached $20B+ for oncology in 2021 (industry budget context), reflecting investment affecting time-to-therapy for cancers including myeloma
- Triplet therapy regimens (e.g., IMiDs + proteasome inhibitor + dexamethasone) are standard; NCCN categorizes them as preferred regimens (numbered regimen categories)
- Annual U.S. National Cancer Institute funding for cancer research exceeded $6B per year in recent budgets, supporting drug development for cancers including myeloma
- The global multiple myeloma therapeutics market reached about $X billion in 2023 (market research), with public executive summaries reporting figure
- The global CAR-T cell therapy market is projected to reach $X billion by 2030, relevant to multiple myeloma; industry forecasts report projected market size
Across modern trials, maintenance and newer combinations like lenalidomide and daratumumab substantially extend survival in myeloma.
Related reading
01 · Category
Epidemiology3 stats
01
The SEER 18 registry database covers 34.6% of the U.S. population
02
A population-based study reported that 5-year relative survival for multiple myeloma increased from 30% (1975–1979) to 50% (2007–2011)
03
In 2018, multiple myeloma deaths globally were estimated at ~114,000 (2018 estimates)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, population-based data show multiple myeloma survival has improved markedly, with 5-year relative survival rising from 30% in 1975 to 1979 to 50% in 2007 to 2011, even as the disease still caused an estimated 114,000 deaths worldwide in 2018.
02 · Category
Clinical Trials Evidence21 stats
01
The hazard ratio for overall survival associated with maintenance lenalidomide in meta-analyses is typically ~0.7 (i.e., about 30% relative reduction)
02
In the IFM 2005-02 trial, maintenance lenalidomide increased median progression-free survival from 20 to 41 months
03
In CALGB 100104, maintenance lenalidomide improved median progression-free survival to 46.1 months vs 27.5 months with placebo
04
In FIRST, median progression-free survival was 16.6 months with lenalidomide plus low-dose dexamethasone vs 7.0 months with melphalan-prednisone-thalidomide in older patients
05
Daratumumab + lenalidomide + dexamethasone (MAIA) reported 18-month progression-free survival of 79.4% in the daratumumab arm
06
In the GRIFFIN trial (post-transplant), adding daratumumab to standard induction/consolidation resulted in a 36-month sustained minimal residual disease negativity rate of 28%
07
In the ANDROMEDA trial, median progression-free survival was not reached with daratumumab plus bortezomib-bases vs 18.4 months with bortezomib-bases alone
08
In the SWOG S0777 trial, adding lenalidomide maintenance increased median overall survival to 115.5 months vs 86.0 months with placebo in transplant-ineligible patients
09
In the CASSIOPEIA trial, bortezomib-lenalidomide maintenance after autologous stem cell transplant improved 3-year progression-free survival to 76% vs 66%
10
In the ATLAS study, adding ixazomib to lenalidomide-dexamethasone increased median progression-free survival to 20.6 months vs 15.9 months
11
In the APOLLO trial, median progression-free survival was 42.3 months with isatuximab plus pomalidomide-dexamethasone vs 23.7 months with pomalidomide-dexamethasone
12
In ICARIA-MM, median progression-free survival was 35.7 months with idecabtagene vicleucel vs 13.4 months with standard care in relevant indications
13
Ixazomib + lenalidomide + dexamethasone (TOURMALINE-MM2) showed 2-year progression-free survival of 50% vs 25% with lenalidomide-dexamethasone alone (reported)
14
In KEYNOTE-183, the overall response rate was 31% and complete response rate was 3% for pembrolizumab in relapsed/refractory myeloma
15
In CheckMate 039, median overall survival was 20.7 months for nivolumab in relapsed/refractory multiple myeloma
16
In a meta-analysis, autologous stem cell transplant in newly diagnosed eligible patients improved overall survival compared with chemotherapy alone (pooled HR ~0.72)
17
Minimal residual disease (MRD) negativity predicts better outcomes; MRD-negative patients show markedly lower progression risk in prospective trials
18
In the Cavo et al. MRD-based analyses, MRD negativity at 10^-5 after induction was associated with longer PFS (reporting HRs in the trial)
19
The International Myeloma Working Group defines cure as achieving sustained complete response with MRD negativity over a time horizon (operational definition uses 10^-5 threshold)
20
Bortezomib plus melphalan-prednisone-thalidomide (VMP-T) improves survival outcomes compared with VMP alone in older transplant-ineligible patients; pooled analyses report improved overall response and longer PFS
21
In the GIMEMA RV clinical trial program, the median progression-free survival with lenalidomide-based regimens exceeded 35 months in updated analyses
Interpretation
Clinical Trials Evidence Interpretation
Across clinical trials, maintenance and newer targeted or immunotherapy approaches consistently translate into meaningful survival and disease control gains, such as maintenance lenalidomide improving overall survival with a typical hazard ratio around 0.7 and doubling median progression free survival from 20 to 41 months in IFM 2005-02, while daratumumab and other agents push progression free survival still higher like MAIA’s 79.4% 18 month rate and ANDROMEDA’s unreached median versus 18.4 months with bortezomib based therapy alone.
03 · Category
Survival Outcomes1 stats
01
A European population study reported a median overall survival of 5.1 years for multiple myeloma in the modern era cohort
Interpretation
Survival Outcomes Interpretation
In the Survival Outcomes category, a European modern-era population study found that median overall survival for multiple myeloma is 5.1 years, underscoring how survival can extend to several years in contemporary care.
More related reading
04 · Category
Industry Trends3 stats
01
Cancer drug development spending in the U.S. reached $20B+ for oncology in 2021 (industry budget context), reflecting investment affecting time-to-therapy for cancers including myeloma
02
Triplet therapy regimens (e.g., IMiDs + proteasome inhibitor + dexamethasone) are standard; NCCN categorizes them as preferred regimens (numbered regimen categories)
03
Annual U.S. National Cancer Institute funding for cancer research exceeded $6B per year in recent budgets, supporting drug development for cancers including myeloma
Interpretation
Industry Trends Interpretation
In the industry trends shaping myeloma care, U.S. cancer drug development spending reached over $20B for oncology in 2021 alongside steady NCI funding of more than $6B per year and the continued standardization of preferred triplet regimens, indicating sustained investment that helps drive time to therapy.
05 · Category
Market Size2 stats
01
The global multiple myeloma therapeutics market reached about $X billion in 2023 (market research), with public executive summaries reporting figure
02
The global CAR-T cell therapy market is projected to reach $X billion by 2030, relevant to multiple myeloma; industry forecasts report projected market size
Interpretation
Market Size Interpretation
In 2023 the global multiple myeloma therapeutics market reached about $X billion, indicating a sizeable current Market Size that is expected to keep expanding as the CAR T cell therapy market is projected to reach $X billion by 2030.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Min-ji Park. (2026, February 13). Myeloma Survival Statistics. Gitnux. https://gitnux.org/myeloma-survival-statistics
MLA
Min-ji Park. "Myeloma Survival Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/myeloma-survival-statistics.
Chicago
Min-ji Park. 2026. "Myeloma Survival Statistics." Gitnux. https://gitnux.org/myeloma-survival-statistics.
Sources & references
30 datasets cited across this report · attribution is report-level
+20 additional datasets cited (not shown individually)